EA199900907A1 - 4,4-дизамещенные 3,4-дигидро-2(1н)-хиназолиноны, полезные в качестве ингибиторов обратной транскриптазы вич - Google Patents

4,4-дизамещенные 3,4-дигидро-2(1н)-хиназолиноны, полезные в качестве ингибиторов обратной транскриптазы вич

Info

Publication number
EA199900907A1
EA199900907A1 EA199900907A EA199900907A EA199900907A1 EA 199900907 A1 EA199900907 A1 EA 199900907A1 EA 199900907 A EA199900907 A EA 199900907A EA 199900907 A EA199900907 A EA 199900907A EA 199900907 A1 EA199900907 A1 EA 199900907A1
Authority
EA
Eurasian Patent Office
Prior art keywords
dihydro
inhibitors
useful
hiv reverse
transpriptase
Prior art date
Application number
EA199900907A
Other languages
English (en)
Other versions
EA001991B1 (ru
Inventor
Джеффри В. Корбетт
Соо Сунг Ко
Original Assignee
Дюпон Фармасьютикалз Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Дюпон Фармасьютикалз Компани filed Critical Дюпон Фармасьютикалз Компани
Publication of EA199900907A1 publication Critical patent/EA199900907A1/ru
Publication of EA001991B1 publication Critical patent/EA001991B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/80—Oxygen atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Настоящее изобретение относится к 4,4-дизамещенным 3,4-дигидро-2(1Н)-хиназолинонам формулы (I)или их стереоизомерным формам, смесям стереомерных форм или их фармацевтически приемлемым солям, которые полезны в качестве ингибиторов обратной транскриптазы ВИЧ, и к их фармацевтическим композициям и диагностическим наборам, содержащим их, и способам применения их для лечения вирусной инфекции или в качестве тест-стандарта или реагента.Отчет о международном поиске опубликован 1999.01.14.
EA199900907A 1997-04-09 1998-04-07 4,4-дизамещенные 3,4-дигидро-2(1н)-хиназолиноны, полезные в качестве ингибиторов обратной транскриптазы вич EA001991B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US83854097A 1997-04-09 1997-04-09
US7132298P 1998-01-14 1998-01-14
PCT/US1998/006733 WO1998045276A2 (en) 1997-04-09 1998-04-07 4,4-disubstituted-3,4-dihydro-2(1h)-quinazolinones useful as hiv reverse transcriptase inhibitors

Publications (2)

Publication Number Publication Date
EA199900907A1 true EA199900907A1 (ru) 2000-04-24
EA001991B1 EA001991B1 (ru) 2001-10-22

Family

ID=26752095

Family Applications (1)

Application Number Title Priority Date Filing Date
EA199900907A EA001991B1 (ru) 1997-04-09 1998-04-07 4,4-дизамещенные 3,4-дигидро-2(1н)-хиназолиноны, полезные в качестве ингибиторов обратной транскриптазы вич

Country Status (19)

Country Link
EP (1) EP0973753A2 (ru)
JP (1) JP2002504095A (ru)
KR (1) KR20010006146A (ru)
CN (1) CN1252063A (ru)
AR (1) AR012340A1 (ru)
AU (1) AU734928B2 (ru)
BR (1) BR9808513A (ru)
CA (1) CA2284996A1 (ru)
EA (1) EA001991B1 (ru)
EE (1) EE9900452A (ru)
HR (1) HRP980143A2 (ru)
HU (1) HUP0001446A3 (ru)
IL (1) IL132188A0 (ru)
NO (1) NO314936B1 (ru)
NZ (1) NZ500592A (ru)
PL (1) PL336305A1 (ru)
SK (1) SK137899A3 (ru)
TW (1) TW587078B (ru)
WO (1) WO1998045276A2 (ru)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002509922A (ja) * 1998-03-27 2002-04-02 デュポン ファーマシューティカルズ カンパニー ４，４−二置換−３，４−ジヒドロ−２（１ｈ）−キナゾリンチオン誘導体、それらの調製法、およびｈｉｖ逆転写酵素阻害剤としてのそれらの使用
AU6508899A (en) 1998-10-13 2000-05-01 Du Pont Pharmaceuticals Company Selective eradication of virally-infected cells by combined use of a cytotoxic agent and an antiviral agent
AU1821900A (en) * 1998-11-19 2000-06-05 Du Pont Pharmaceuticals Company Process for the preparation of quinazolinones
WO2000029390A1 (en) * 1998-11-19 2000-05-25 Du Pont Pharmaceuticals Company Crystalline (-)-6- chloro-4- cyclopropylethynyl- 4-trifluoromethyl- 3,4-dihydro- 2(1h)-quinazolinone
US6175009B1 (en) 1999-11-18 2001-01-16 Dupont Pharmaceuticals Company Process for the preparation of quinazolinones
DE60023025T2 (de) * 1999-11-23 2006-07-13 Smithkline Beecham Corp. 3,4-dihydro-(1h)chinazolin-2-on-verbindungen als csbp/p39-kinase-inhibitoren
US6759410B1 (en) 1999-11-23 2004-07-06 Smithline Beecham Corporation 3,4-dihydro-(1H)-quinazolin-2-ones and their use as CSBP/p38 kinase inhibitors
CA2403230A1 (en) * 2000-03-23 2001-09-27 Lilian A. Radesca Asymmetric synthesis of quinazolin-2-ones useful as hiv reverse transcriptase inhibitors
US6555686B2 (en) * 2000-03-23 2003-04-29 Bristol-Myers Squibb Pharma Asymmetric synthesis of quinazolin-2-ones useful as HIV reverse transcriptase inhibitors
ZA200300255B (en) 2000-07-20 2004-09-28 Bristol Myers Squibb Pharma Co Tricyclic 2-pyridone compounds useful as HIV reverse transcriptase inhibitors.
US6596729B2 (en) 2000-07-20 2003-07-22 Bristol-Myers Squibb Company Tricyclic-2-pyridone compounds useful as HIV reverse transcriptase inhibitors
US8641644B2 (en) 2000-11-21 2014-02-04 Sanofi-Aventis Deutschland Gmbh Blood testing apparatus having a rotatable cartridge with multiple lancing elements and testing means
US9226699B2 (en) 2002-04-19 2016-01-05 Sanofi-Aventis Deutschland Gmbh Body fluid sampling module with a continuous compression tissue interface surface
US9427532B2 (en) 2001-06-12 2016-08-30 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
US9795747B2 (en) 2010-06-02 2017-10-24 Sanofi-Aventis Deutschland Gmbh Methods and apparatus for lancet actuation
US7041068B2 (en) 2001-06-12 2006-05-09 Pelikan Technologies, Inc. Sampling module device and method
US8702624B2 (en) 2006-09-29 2014-04-22 Sanofi-Aventis Deutschland Gmbh Analyte measurement device with a single shot actuator
US8784335B2 (en) 2002-04-19 2014-07-22 Sanofi-Aventis Deutschland Gmbh Body fluid sampling device with a capacitive sensor
US7547287B2 (en) 2002-04-19 2009-06-16 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US9314194B2 (en) 2002-04-19 2016-04-19 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
US8579831B2 (en) 2002-04-19 2013-11-12 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
US9248267B2 (en) 2002-04-19 2016-02-02 Sanofi-Aventis Deustchland Gmbh Tissue penetration device
US9795334B2 (en) 2002-04-19 2017-10-24 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
US7713214B2 (en) 2002-04-19 2010-05-11 Pelikan Technologies, Inc. Method and apparatus for a multi-use body fluid sampling device with optical analyte sensing
EP1575583A1 (en) * 2002-12-16 2005-09-21 Boehringer Ingelheim Pharmaceuticals Inc. Treatment of hiv infection through combined administration of tipranavir and capravirine
US8574895B2 (en) 2002-12-30 2013-11-05 Sanofi-Aventis Deutschland Gmbh Method and apparatus using optical techniques to measure analyte levels
WO2006001797A1 (en) 2004-06-14 2006-01-05 Pelikan Technologies, Inc. Low pain penetrating
US8282576B2 (en) 2003-09-29 2012-10-09 Sanofi-Aventis Deutschland Gmbh Method and apparatus for an improved sample capture device
EP1680014A4 (en) 2003-10-14 2009-01-21 Pelikan Technologies Inc METHOD AND APPARATUS PROVIDING A VARIABLE USER INTERFACE
EP1706026B1 (en) 2003-12-31 2017-03-01 Sanofi-Aventis Deutschland GmbH Method and apparatus for improving fluidic flow and sample capture
EP1751546A2 (en) 2004-05-20 2007-02-14 Albatros Technologies GmbH & Co. KG Printable hydrogel for biosensors
US9775553B2 (en) 2004-06-03 2017-10-03 Sanofi-Aventis Deutschland Gmbh Method and apparatus for a fluid sampling device
EP1765194A4 (en) 2004-06-03 2010-09-29 Pelikan Technologies Inc METHOD AND APPARATUS FOR MANUFACTURING A DEVICE FOR SAMPLING LIQUIDS
WO2009126900A1 (en) 2008-04-11 2009-10-15 Pelikan Technologies, Inc. Method and apparatus for analyte detecting device
US9375169B2 (en) 2009-01-30 2016-06-28 Sanofi-Aventis Deutschland Gmbh Cam drive for managing disposable penetrating member actions with a single motor and motor and control system
US8440693B2 (en) 2009-12-22 2013-05-14 Novartis Ag Substituted isoquinolinones and quinazolinones
US8965476B2 (en) 2010-04-16 2015-02-24 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
CN102060786A (zh) * 2011-01-20 2011-05-18 天津大学 4-(取代-1,3-二炔基)-4-(三氟甲基)-3,4-二氢取代喹唑啉-2-酮类化合物及其制备方法和应用
DK2694101T3 (en) * 2011-04-06 2017-01-09 Biovaxim Ltd Pharmaceutical compositions for the prevention and / or treatment of HIV disease in humans
WO2013175417A1 (en) 2012-05-24 2013-11-28 Novartis Ag Pyrrolopyrrolidinone compounds
US9403827B2 (en) 2013-01-22 2016-08-02 Novartis Ag Substituted purinone compounds
EP2948453B1 (en) 2013-01-22 2017-08-02 Novartis AG Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the p53/mdm2 interaction
US9890166B2 (en) 2013-05-27 2018-02-13 Novartis Ag Imidazopyrrolidine derivatives and their use in the treatment of disease
EA028175B1 (ru) 2013-05-28 2017-10-31 Новартис Аг Производные пиразолопирролидин-4-она в качестве ингибиторов вет и их применение при лечении заболевания
AU2014272700B2 (en) 2013-05-28 2016-12-01 Novartis Ag Pyrazolo-pyrrolidin-4-one derivatives and their use in the treatment of disease
EA029269B1 (ru) 2013-11-21 2018-02-28 Новартис Аг Производные пирролопирролона и их применение для лечения заболеваний

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL102764A0 (en) * 1991-08-16 1993-01-31 Merck & Co Inc Quinazoline derivatives,and pharmaceutical compositions containing them
AU2436792A (en) * 1991-08-16 1993-03-16 Merck & Co., Inc. Quinazoline derivatives as inhibitors of hiv reverse transcriptase
WO1993022292A1 (en) * 1992-05-07 1993-11-11 Merck & Co., Inc. New quinazolines as inhibitors of hiv reverse transcriptase
US5663169A (en) * 1992-08-07 1997-09-02 Merck & Co., Inc. Benzoxazinones as inhibitors of HIV reverse transcriptase
DE4320347A1 (de) * 1993-06-19 1994-12-22 Boehringer Mannheim Gmbh Quinazolin-Derivate und diese enthaltende Arzneimittel
GB2281297A (en) * 1993-08-27 1995-03-01 Merck & Co Inc Quinazoline compounds
WO1995012583A1 (en) * 1993-11-05 1995-05-11 Merck & Co., Inc. New quinazolines as inhibitors of hiv reverse transcriptase
US5434152A (en) * 1993-11-08 1995-07-18 Merck & Co., Inc. Asymmetric synthesis of (S)-(-)-6-chloro-4- cyclopropyl-3,4-dihydro-4-[(2-pyridyl)ethynyl]-2(1H)-quinazolinone

Also Published As

Publication number Publication date
EE9900452A (et) 2000-04-17
SK137899A3 (en) 2000-05-16
NO994904L (no) 1999-12-01
EP0973753A2 (en) 2000-01-26
HUP0001446A3 (en) 2001-11-28
BR9808513A (pt) 2000-05-23
HUP0001446A2 (hu) 2001-05-28
HRP980143A2 (en) 1999-02-28
JP2002504095A (ja) 2002-02-05
KR20010006146A (ko) 2001-01-26
IL132188A0 (en) 2001-03-19
PL336305A1 (en) 2000-06-19
TW587078B (en) 2004-05-11
WO1998045276A3 (en) 1999-01-14
AR012340A1 (es) 2000-10-18
CA2284996A1 (en) 1998-10-15
WO1998045276A2 (en) 1998-10-15
EA001991B1 (ru) 2001-10-22
NZ500592A (en) 2001-09-28
AU6796098A (en) 1998-10-30
AU734928B2 (en) 2001-06-28
NO994904D0 (no) 1999-10-08
CN1252063A (zh) 2000-05-03
NO314936B1 (no) 2003-06-16

Similar Documents

Publication Publication Date Title
EA199900907A1 (ru) 4,4-дизамещенные 3,4-дигидро-2(1н)-хиназолиноны, полезные в качестве ингибиторов обратной транскриптазы вич
EA200200471A1 (ru) Конденсированные нафтиридины в качестве ингибиторов обратной транскриптазы вич
EA200400023A1 (ru) Ингибиторы вич-протеазы, содержащие их композиции, их фармацевтическое использование и материалы для их синтеза
DE69724630D1 (de) 4,4-disubstituierte 1,4-dihydro-2h-3,1-benzoxazin-2-one die anwendbar sind als hiv-reverstranskriptase-inhibitoren, zwischenprodukte und verfahren zu ihrer herstellung
EA200300943A1 (ru) Производные пиразола для лечения инфекции вируса иммунодефицита человека (вич)
ATE260103T1 (de) Ortho-anthranilamide derivate als antikoagulantien
EA199900746A1 (ru) Дизамещенные бициклические гетероциклы, их получение и применение в качестве лекарственных средств
DK1140918T3 (da) Thrombininhibitorer
EA200201179A1 (ru) Производные 2-аминокарбонил-9h-пурина
EA199800752A1 (ru) Пентафторбензолсульфонамиды и их аналоги
PT923554E (pt) N-benzilpiperidina e derivados tetrahidropiridina
ATE377602T1 (de) Morphinanderivate und ihre medizinische anwendung
TR200000993T2 (tr) Endotelin antagonistleri.
BR9712707A (pt) Derivados de ácido 4-bifenil-4-hidroxibutìrico substituìdo com inibidores de metaloprotease de matriz
YU62504A (sh) Triciklična 2-pirimidonska jedinjenja korisna kao inhibitori hiv reverzne transkriptoze
EA199800661A1 (ru) Ингибиторы аспартильных протеаз
EA200400806A1 (ru) Способ получения эхинокандиновых соединений
WO2004002410A3 (en) 2,4-disubstituted-pyridine n-oxides useful as hiv reverse transcriptase inhibitors
EA200400049A1 (ru) Оксадиазольные и тиадиазольные производные пирролидина
MXPA03000434A (es) Compuestos de 2-piridona triciclicos utiles como inhibidores de transcriptasa inversa del virus de inmunodeficiencia humana (vih).
EA200300400A1 (ru) 17α-ФТОРАЛКИЛСТЕРОИДЫ, СПОСОБ ИХ ПОЛУЧЕНИЯ И СОДЕРЖАЩИЕ ЭТИ СОЕДИНЕНИЯ ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ
EA199900452A1 (ru) 1-(3-аминоиндазол-5-ил)-3-фенилметилциклические мочевины, полезные в качестве ингибиторов вич-протеазы
EA200500287A1 (ru) Производные 4-(3, 5-дицианофенокси)пиразола для применения в качестве модуляторов обратной транскриптазы в лечении, в числе прочего, вич-инфекции
EA199900451A1 (ru) (4r,5s,6s,7r)-гексагидро-1-[5-(3-аминоиндазол)метил]-3-бутил-5,6-дигидрокси-4,7-бис[фенилметил]-2н-1,3-диазепин-2-он, его получение и его применение в качестве ингибитора вич-протеазы
WO2000073284A3 (en) 1,4-benzodiazepin-2-ones useful as hiv reverse transcriptase inhibitors

Legal Events

Date Code Title Description
PC4A Registration of transfer of a eurasian patent by assignment
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU